Challenges of Pancreatic Cancer.
Challenges of Pancreatic Cancer.
复制标题
DOI：
10.1097/ppo.0000000000000109
复制
发表时间：
2015-05
期刊：
影响因子：
--
通讯作者：
Kelly KA
中科院分区：
文献类型：
--
作者：
Dimastromatteo J;Houghton JL;Lewis JS;Kelly KA
近年来，新型分子肿瘤显像剂的开发取得了相当大的进展。许多癌症显像剂已经证明了在临床前阶段辅助诊断、分期和治疗计划的巨大潜力，这反过来又导致许多药物被批准用于人体试验。胰腺导管腺癌（PDAC）是目前最常见的恶性肿瘤，5年生存率约为6%。随着检测技术的进步，对能够在早期阶段进行诊断的分子成像工具的需求对于改善患者预后至关重要。在这篇综述中，我们将突出的代理人，照亮各种细胞群体，包括肿瘤：上皮，内皮和间质肿瘤细胞。
The development of novel molecular cancer imaging agents has considerably advanced in recent years. Numerous cancer imaging agents have demonstrated remarkable potential for aiding the diagnosis, staging, and treatment planning at the preclinical stage which in turn has led to a number of agents being approved for human trials. Pancreatic ductal adenocarcinoma (PDAC) is currently the most deadly common carcinoma with an overall 5-year survival rate of about 6%. As detection technologies progress, the need for molecular imaging tools that will allow the diagnosis at an early stage will be crucial to improving patient outcomes. In this review, we will highlight agents that illuminate various cell populations that comprise the tumor: epithelial, endothelial, and stromal tumor cells.